CompletedPhase 1NCT04578600

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Joseph Tuscano
Principal Investigator
Joseph M Tuscano, M.D
University of California, Davis
Intervention
Lenalidomide(drug)
Enrollment
8 enrolled
Eligibility
18 years · All sexes
Timeline
2020 – 2025

Study locations (1)

Collaborators

National Cancer Institute (NCI) · Celgene

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04578600 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials